Lecanemab Conversion From Accelerated To Full Approval Could Be Among Fastest Ever

 
• By Bridget Silverman

Biogen/Eisai’s Phase III data is on track for a Q1 2023 submission, potentially just weeks after lecanemab is expected to gain accelerated approval for early Alzheimer’s.

brain over the finish line
Lecanemab could be one of the fastest accelerated approvals to cross the full approval finish line. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

More from Approval Standards

More from Pathways & Standards